CN107837240A - 一种治疗高血压的盐酸马尼地平片剂及其制备方法 - Google Patents
一种治疗高血压的盐酸马尼地平片剂及其制备方法 Download PDFInfo
- Publication number
- CN107837240A CN107837240A CN201711321317.5A CN201711321317A CN107837240A CN 107837240 A CN107837240 A CN 107837240A CN 201711321317 A CN201711321317 A CN 201711321317A CN 107837240 A CN107837240 A CN 107837240A
- Authority
- CN
- China
- Prior art keywords
- tablet
- preparation
- macrogol
- weight
- rotating speeds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XVIXARVAOCTOLU-BVNFUTIRSA-N chembl312176 Chemical compound CC=1N=C(C)C(=C(O)/OC)/C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1C(=O)OCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 XVIXARVAOCTOLU-BVNFUTIRSA-N 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003511 macrogol Drugs 0.000 claims abstract description 23
- 238000001035 drying Methods 0.000 claims abstract description 19
- 238000004090 dissolution Methods 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 238000010792 warming Methods 0.000 claims abstract description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 6
- 238000010410 dusting Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 14
- 206010013786 Dry skin Diseases 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- -1 Sodium alkyl sulfonate Chemical class 0.000 claims description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims description 2
- 229960003963 manidipine Drugs 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 abstract description 3
- 239000000155 melt Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 8
- 230000003068 static effect Effects 0.000 description 6
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical class OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711321317.5A CN107837240B (zh) | 2017-12-12 | 2017-12-12 | 一种治疗高血压的盐酸马尼地平片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711321317.5A CN107837240B (zh) | 2017-12-12 | 2017-12-12 | 一种治疗高血压的盐酸马尼地平片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107837240A true CN107837240A (zh) | 2018-03-27 |
CN107837240B CN107837240B (zh) | 2020-07-07 |
Family
ID=61663967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711321317.5A Active CN107837240B (zh) | 2017-12-12 | 2017-12-12 | 一种治疗高血压的盐酸马尼地平片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107837240B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110812336A (zh) * | 2018-08-07 | 2020-02-21 | 迪沙药业集团(天津)药物研究有限公司 | 一种他达拉非片剂组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050238712A1 (en) * | 1999-06-18 | 2005-10-27 | Kazuhiro Ohkouchi | Quickly disintegrating solid preparations |
CN1839850A (zh) * | 2006-01-18 | 2006-10-04 | 马志梅 | 含谷维素的分散片剂药物及其制备方法 |
CN101361736A (zh) * | 2008-10-08 | 2009-02-11 | 北京理工大学 | 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方 |
CN103120651A (zh) * | 2011-11-21 | 2013-05-29 | 四川海思科制药有限公司 | 一种马尼地平片剂 |
CN104127407A (zh) * | 2014-08-15 | 2014-11-05 | 朗天药业(湖北)有限公司 | 一种水飞蓟素化合物及含有该提取物的药物组合物 |
-
2017
- 2017-12-12 CN CN201711321317.5A patent/CN107837240B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050238712A1 (en) * | 1999-06-18 | 2005-10-27 | Kazuhiro Ohkouchi | Quickly disintegrating solid preparations |
CN1839850A (zh) * | 2006-01-18 | 2006-10-04 | 马志梅 | 含谷维素的分散片剂药物及其制备方法 |
CN101361736A (zh) * | 2008-10-08 | 2009-02-11 | 北京理工大学 | 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方 |
CN103120651A (zh) * | 2011-11-21 | 2013-05-29 | 四川海思科制药有限公司 | 一种马尼地平片剂 |
CN104127407A (zh) * | 2014-08-15 | 2014-11-05 | 朗天药业(湖北)有限公司 | 一种水飞蓟素化合物及含有该提取物的药物组合物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110812336A (zh) * | 2018-08-07 | 2020-02-21 | 迪沙药业集团(天津)药物研究有限公司 | 一种他达拉非片剂组合物 |
CN110812336B (zh) * | 2018-08-07 | 2021-09-10 | 迪沙药业集团有限公司 | 一种他达拉非片剂组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN107837240B (zh) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI307632B (en) | Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof | |
JP5674275B2 (ja) | 活性成分の放出時間が長い組成物、その調製方法および利用方法 | |
SI21394A2 (sl) | Farmacevtske pelete, ki vsebujejo tamsulozin | |
CN102740836A (zh) | 用于制备商品化纳米颗粒和微粒粉末的方法 | |
CN101896167B (zh) | 药物组合物 | |
US20190240160A1 (en) | Acid resistant capsules | |
EP1220658A1 (en) | Melt granulated composition and modified release dosage form prepared from said composition | |
JP2013536821A (ja) | 活性化合物含有顆粒及び投与剤形の調製における、アミノ含有ポリマーに基づくコポリマーのマトリックス結合剤としての使用 | |
WO2019106043A1 (en) | Pharmaceutical composition comprising obeticholic acid | |
WO1997003656A1 (fr) | Preparation granulaire et son procede de production | |
JPH03500288A (ja) | 徐放性ニフェジピン製剤 | |
CN107837240A (zh) | 一种治疗高血压的盐酸马尼地平片剂及其制备方法 | |
CN102462663A (zh) | 一种基于干法制粒的非洛地平药用组合物 | |
CN104661652B (zh) | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 | |
BR112013020877B1 (pt) | Processo para produzir composições de revestimento pulverulentas | |
BR112013021510B1 (pt) | Processo para a produção de composições de revestimento em pó, e, uso de um pó de polímero | |
CN104758180A (zh) | 一种复方制剂胶囊的二次填充方法 | |
JP2014221847A (ja) | 糖衣製剤およびその製造方法 | |
CN108743554A (zh) | 一种甲苯磺酸依度沙班片剂及其制备方法 | |
JP2004277431A (ja) | 粒状製剤及びその製造法 | |
JP2018104425A (ja) | ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する錠剤 | |
CN116893086A (zh) | 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法 | |
CN106580924A (zh) | 一种马来酸氨氯地平的多单元释放药物组合物及其制备方法 | |
CN104684545B (zh) | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 | |
CN106580905A (zh) | 一种他喷他多缓释药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Yibin Inventor after: Sun Yidong Inventor after: Geng Zhi Inventor before: Sun Yidong Inventor before: Geng Zhi |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200609 Address after: 528244 Guangdong province Lishui Town Nanhai District Foshan city Chong Industrial Zone Applicant after: Foshan Derek Pharmaceutical Co., Ltd Address before: 276017 Shandong Linyi Luozhuang District high tech Zone bio Pharmaceutical Industrial Park Applicant before: LINYI QIZE MEDICINE TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |